Cystic Fibrosis Therapies Stocks
Biotechnology and medical device developers in this cohort target the underlying genetic defects and chronic pulmonary complications associated with cystic fibrosis, a high-value orphan disease market characterized by high barriers to entry and strong payer support.
As of Oct 23, 2026, Cystic Fibrosis Therapies has 8 US-listed companies worth $146B combined. The median member moved -1.8% over the past week; ARMP led at +8.0% and SION trailed at -7.5%.
Companies in Cystic Fibrosis Therapies
- VRTX – Vertex Pharmaceuticals Inc, $136B
- KRYS – Krystal Biotech Inc, $9.6B
- ARCT – Arcturus Therapeutics Holdings Inc, $308M
- ELMD – Electromed Inc, $231M
- SION – Sionna Therapeutics, Inc. Common Stock, $187M
- ARMP – Armata Pharmaceuticals Inc, $103M
- ELOX – Eloxx Pharmaceuticals, Inc., $53M
- ARDS – Aridis Pharmaceuticals Inc, $4,457